Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Patricia Donahoe, M.D.

TitleMarshall K. Bartlett Professor of Surgery
InstitutionMassachusetts General Hospital
DepartmentSurgery
AddressMassachusetts General Hospital
Dir. Pediatric Surgical Research Laboratories CPZN 6206
185 Cambridge St
Boston MA 02114
Phone617/724-1600
Fax617/726-5057

 Mentoring 
 current student opportunities
Available: 09/01/13, Expires: 08/30/15

Isolation of stem cells ascites, determination of mechanisms of action of Mullerian Inhibting Substance against stem cell population. Student projects will vary depending on stage of project, student's interest.

Available: 07/01/11, Expires: 06/30/16

Use of RNAi in mice, chicks, and Drosophilia models, and in patient-specific IPS cells to predict function of candidate genes as causative for Congenital Diaphragmatic Hernia. Student projects will vary depending on stage of project and student's interest.

Available: 07/01/11, Expires: 06/30/16

Defining the genetic causes of Congenital Diaphragamatic Hernia using next generation sequencing, array CGH, in classical genetics, coupled with bioinformatic analyses.

 completed student projects
Mutational Analysis of patients with Huma Ovarian Cancer for p16 and E2F1 Genes
Summer, 06/18/01 - 08/10/01
Developing statistical models for reconstructing patient haplotypes from a maximally informative set of tag SNPs
Summer, 06/01/04 - 09/01/04
MIS Mediated signaling in Proliferation and Apoptosisof the Normal Breast
Summer, 06/25/01 - 08/17/01
The Transformation of Human Fimbria Cells to Tumorgenic Serous Carcinoma Cells
Summer, 06/15/08 - 08/15/08
Genetic Mechanisms Underlying Lung Hypoplasia in Congenital Diaphragmatic Hernia
Summer, 05/21/09 - 08/28/09
Sialyl Acetyl Esterase: A Regulator of Humoral Immune Responses and Susceptibility to Lupus
Summer, 05/30/06 - 09/01/06

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Park JH, Tanaka Y, Arango NA, Zhang L, Benedict LA, Roh MI, Donahoe PK, Teixeira JM. Induction of WNT inhibitory factor 1 expression by Müllerian inhibiting substance/antiMullerian hormone in the Müllerian duct mesenchyme is linked to Müllerian duct regression. Dev Biol. 2014 Feb 1; 386(1):227-36.
    View in: PubMed
  2. Arango NA, Li L, Dabir D, Nicolau F, Pieretti-Vanmarcke R, Koehler C, McCarrey JR, Lu N, Donahoe PK. Meiosis I arrest abnormalities lead to severe oligozoospermia in meiosis 1 arresting protein (m1ap)-deficient mice. Biol Reprod. 2013; 88(3):76.
    View in: PubMed
  3. Longoni M, Lage K, Russell MK, Loscertales M, Abdul-Rahman OA, Baynam G, Bleyl SB, Brady PD, Breckpot J, Chen CP, Devriendt K, Gillessen-Kaesbach G, Grix AW, Rope AF, Shimokawa O, Strauss B, Wieczorek D, Zackai EH, Coletti CM, Maalouf FI, Noonan KM, Park JH, Tracy AA, Lee C, Donahoe PK, Pober BR. Congenital diaphragmatic hernia interval on chromosome 8p23.1 characterized by genetics and protein interaction networks. Am J Med Genet A. 2012 Dec; 158A(12):3148-58.
    View in: PubMed
  4. Lage K, Greenway SC, Rosenfeld JA, Wakimoto H, Gorham JM, Segrè AV, Roberts AE, Smoot LB, Pu WT, Pereira AC, Mesquita SM, Tommerup N, Brunak S, Ballif BC, Shaffer LG, Donahoe PK, Daly MJ, Seidman JG, Seidman CE, Larsen LA. Genetic and environmental risk factors in congenital heart disease functionally converge in protein networks driving heart development. Proc Natl Acad Sci U S A. 2012 Aug 28; 109(35):14035-40.
    View in: PubMed
  5. Namkung J, Song JY, Jo HH, Kim MR, Lew YO, Donahoe PK, MacLaughlin DT, Kim JH. Mullerian inhibiting substance induces apoptosis of human endometrial stromal cells in endometriosis. J Clin Endocrinol Metab. 2012 Sep; 97(9):3224-30.
    View in: PubMed
  6. Song JY, Jo HH, Kim MR, Lew YO, Ryu KS, Cha JH, Kang CS, Donahoe PK, Maclaughlin DT, Kim JH. Expression of Müllerian inhibiting substance type II receptor and antiproliferative effects of MIS on human cervical cancer. Int J Oncol. 2012 Jun; 40(6):2013-21.
    View in: PubMed
  7. Russell MK, Longoni M, Wells J, Maalouf FI, Tracy AA, Loscertales M, Ackerman KG, Pober BR, Lage K, Bult CJ, Donahoe PK. Congenital diaphragmatic hernia candidate genes derived from embryonic transcriptomes. Proc Natl Acad Sci U S A. 2012 Feb 21; 109(8):2978-83.
    View in: PubMed
  8. Meirelles K, Benedict LA, Dombkowski D, Pepin D, Preffer FI, Teixeira J, Tanwar PS, Young RH, MacLaughlin DT, Donahoe PK, Wei X. Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance. Proc Natl Acad Sci U S A. 2012 Feb 14; 109(7):2358-63.
    View in: PubMed
  9. Hwang SJ, Suh MJ, Yoon JH, Kim MR, Ryu KS, Nam SW, Donahoe PK, Maclaughlin DT, Kim JH. Identification of characteristic molecular signature of Müllerian inhibiting substance in human HPV-related cervical cancer cells. Int J Oncol. 2011 Oct; 39(4):811-20.
    View in: PubMed
  10. Pinto D, Darvishi K, Shi X, Rajan D, Rigler D, Fitzgerald T, Lionel AC, Thiruvahindrapuram B, Macdonald JR, Mills R, Prasad A, Noonan K, Gribble S, Prigmore E, Donahoe PK, Smith RS, Park JH, Hurles ME, Carter NP, Lee C, Scherer SW, Feuk L. Comprehensive assessment of array-based platforms and calling algorithms for detection of copy number variants. Nat Biotechnol. 2011 Jun; 29(6):512-20.
    View in: PubMed
  11. Clarkson AN, Talbot CL, Wang PY, MacLaughlin DT, Donahoe PK, McLennan IS. Müllerian inhibiting substance is anterogradely transported and does not attenuate avulsion-induced death of hypoglossal motor neurons. Exp Neurol. 2011 Oct; 231(2):304-8.
    View in: PubMed
  12. Chang HL, Pieretti-Vanmarcke R, Nicolaou F, Li X, Wei X, MacLaughlin DT, Donahoe PK. Mullerian inhibiting substance inhibits invasion and migration of epithelial cancer cell lines. Gynecol Oncol. 2011 Jan; 120(1):128-34.
    View in: PubMed
  13. Wei X, Dombkowski D, Meirelles K, Pieretti-Vanmarcke R, Szotek PP, Chang HL, Preffer FI, Mueller PR, Teixeira J, MacLaughlin DT, Donahoe PK. Mullerian inhibiting substance preferentially inhibits stem/progenitors in human ovarian cancer cell lines compared with chemotherapeutics. Proc Natl Acad Sci U S A. 2010 Nov 2; 107(44):18874-9.
    View in: PubMed
  14. Kantarci S, Ackerman KG, Russell MK, Longoni M, Sougnez C, Noonan KM, Hatchwell E, Zhang X, Pieretti Vanmarcke R, Anyane-Yeboa K, Dickman P, Wilson J, Donahoe PK, Pober BR. Characterization of the chromosome 1q41q42.12 region, and the candidate gene DISP1, in patients with CDH. Am J Med Genet A. 2010 Oct; 152A(10):2493-504.
    View in: PubMed
  15. Tanwar PS, Zhang L, Tanaka Y, Taketo MM, Donahoe PK, Teixeira JM. Focal Mullerian duct retention in male mice with constitutively activated beta-catenin expression in the Mullerian duct mesenchyme. Proc Natl Acad Sci U S A. 2010 Sep 14; 107(37):16142-7.
    View in: PubMed
  16. Lage K, Møllgård K, Greenway S, Wakimoto H, Gorham JM, Workman CT, Bendsen E, Hansen NT, Rigina O, Roque FS, Wiese C, Christoffels VM, Roberts AE, Smoot LB, Pu WT, Donahoe PK, Tommerup N, Brunak S, Seidman CE, Seidman JG, Larsen LA. Dissecting spatio-temporal protein networks driving human heart development and related disorders. Mol Syst Biol. 2010 Jun 22; 6:381.
    View in: PubMed
  17. MacLaughlin DT, Donahoe PK. Müllerian inhibiting substance/anti-Müllerian hormone: a potential therapeutic agent for human ovarian and other cancers. Future Oncol. 2010 Mar; 6(3):391-405.
    View in: PubMed
  18. Hayashida T, Takahashi F, Chiba N, Brachtel E, Takahashi M, Godin-Heymann N, Gross KW, Vivanco Md, Wijendran V, Shioda T, Sgroi D, Donahoe PK, Maheswaran S. HOXB9, a gene overexpressed in breast cancer, promotes tumorigenicity and lung metastasis. Proc Natl Acad Sci U S A. 2010 Jan 19; 107(3):1100-5.
    View in: PubMed
  19. Chang HL, Senaratne TN, Zhang L, Szotek PP, Stewart E, Dombkowski D, Preffer F, Donahoe PK, Teixeira J. Uterine leiomyomas exhibit fewer stem/progenitor cell characteristics when compared with corresponding normal myometrium. Reprod Sci. 2010 Feb; 17(2):158-67.
    View in: PubMed
  20. Papakostas TD, Pieretti-Vanmarcke R, Nicolaou F, Thanos A, Trichonas G, Koufomichali X, Anago K, Donahoe PK, Teixeira J, MacLaughlin DT, Vavvas D. Development of an efficiently cleaved, bioactive, highly pure FLAG-tagged recombinant human Mullerian Inhibiting Substance. Protein Expr Purif. 2010 Mar; 70(1):32-8.
    View in: PubMed
  21. Donahoe PK. A pediatric surgeon retools in genetics and genomics to study congenital diaphragmatic hernia. J Pediatr Surg. 2009 Feb; 44(2):307-11.
    View in: PubMed
  22. Donahoe PK, Noonan KM, Lage K. Genetic tools and algorithms for gene discovery in major congenital anomalies. Birth Defects Res A Clin Mol Teratol. 2009 Jan; 85(1):6-12.
    View in: PubMed
  23. Lage K, Hansen NT, Karlberg EO, Eklund AC, Roque FS, Donahoe PK, Szallasi Z, Jensen TS, Brunak S. A large-scale analysis of tissue-specific pathology and gene expression of human disease genes and complexes. Proc Natl Acad Sci U S A. 2008 Dec 30; 105(52):20870-5.
    View in: PubMed
  24. Akihiro Fujino, Nelson A. Arango, Yong Zhan, Thomas F. Manganaro, Xianlin Li, David T. MacLaughlin, Patricia K. Donahoe. Developmental Biology. Cell migration and activated PI3K/AKT-directed elongation in the developing rat. 2008; (325):351-362.
  25. Fujino A, Arango NA, Zhan Y, Manganaro TF, Li X, MacLaughlin DT, Donahoe PK. Cell migration and activated PI3K/AKT-directed elongation in the developing rat Müllerian duct. Dev Biol. 2009 Jan 15; 325(2):351-62.
    View in: PubMed
  26. Szotek PP, Chang HL, Brennand K, Fujino A, Pieretti-Vanmarcke R, Lo Celso C, Dombkowski D, Preffer F, Cohen KS, Teixeira J, Donahoe PK. Normal ovarian surface epithelial label-retaining cells exhibit stem/progenitor cell characteristics. Proc Natl Acad Sci U S A. 2008 Aug 26; 105(34):12469-73.
    View in: PubMed
  27. Kantarci S, Ragge NK, Thomas NS, Robinson DO, Noonan KM, Russell MK, Donnai D, Raymond FL, Walsh CA, Donahoe PK, Pober BR. Donnai-Barrow syndrome (DBS/FOAR) in a child with a homozygous LRP2 mutation due to complete chromosome 2 paternal isodisomy. Am J Med Genet A. 2008 Jul 15; 146A(14):1842-7.
    View in: PubMed
  28. Loscertales M, Mikels AJ, Hu JK, Donahoe PK, Roberts DJ. Chick pulmonary Wnt5a directs airway and vascular tubulogenesis. Development. 2008 Apr; 135(7):1365-76.
    View in: PubMed
  29. Donahoe PK. The mandate for innovation in pediatric surgery; creating the environment for success, parity, and excellence. J Pediatr Surg. 2008 Jan; 43(1):1-7.
    View in: PubMed
  30. Renlund N, Pieretti-Vanmarcke R, O'Neill FH, Zhang L, Donahoe PK, Teixeira J. c-Jun N-terminal kinase inhibitor II (SP600125) activates Mullerian inhibiting substance type II receptor-mediated signal transduction. Endocrinology. 2008 Jan; 149(1):108-15.
    View in: PubMed
  31. Aidlen JT, Nazarey PP, Kinane TB, Donahoe PK, Schnitzer JJ, Kling DE. Retinoic acid-mediated differentiation protects against nitrofen-induced apoptosis. Birth Defects Res B Dev Reprod Toxicol. 2007 Oct; 80(5):406-16.
    View in: PubMed
  32. Kantarci S, Al-Gazali L, Hill RS, Donnai D, Black GC, Bieth E, Chassaing N, Lacombe D, Devriendt K, Teebi A, Loscertales M, Robson C, Liu T, MacLaughlin DT, Noonan KM, Russell MK, Walsh CA, Donahoe PK, Pober BR. Mutations in LRP2, which encodes the multiligand receptor megalin, cause Donnai-Barrow and facio-oculo-acoustico-renal syndromes. Nat Genet. 2007 Aug; 39(8):957-9.
    View in: PubMed
  33. Fujino A, Pieretti-Vanmarcke R, Wong A, Donahoe PK, Arango NA. Sexual dimorphism of G-protein subunit Gng13 expression in the cortical region of the developing mouse ovary. Dev Dyn. 2007 Jul; 236(7):1991-6.
    View in: PubMed
  34. Kantarci S, Donahoe PK. Congenital diaphragmatic hernia (CDH) etiology as revealed by pathway genetics. Am J Med Genet C Semin Med Genet. 2007 May 15; 145C(2):217-26.
    View in: PubMed
  35. Gupta V, Yeo G, Kawakubo H, Rangnekar V, Ramaswamy P, Hayashida T, MacLaughlin DT, Donahoe PK, Maheswaran S. Mullerian-inhibiting substance induces Gro-beta expression in breast cancer cells through a nuclear factor-kappaB-dependent and Smad1-dependent mechanism. Cancer Res. 2007 Mar 15; 67(6):2747-56.
    View in: PubMed
  36. Szotek PP, Chang HL, Zhang L, Preffer F, Dombkowski D, Donahoe PK, Teixeira J. Adult mouse myometrial label-retaining cells divide in response to gonadotropin stimulation. Stem Cells. 2007 May; 25(5):1317-25.
    View in: PubMed
  37. Kow LM, Florea C, Schwanzel-Fukuda M, Devidze N, Kami Kia H, Lee A, Zhou J, Maclaughlin D, Donahoe P, Pfaff D. Development of a sexually differentiated behavior and its underlying CNS arousal functions. Curr Top Dev Biol. 2007; 79:37-59.
    View in: PubMed
  38. Pieretti-Vanmarcke R, Donahoe PK, Pearsall LA, Dinulescu DM, Connolly DC, Halpern EF, Seiden MV, MacLaughlin DT. Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer. Proc Natl Acad Sci U S A. 2006 Nov 14; 103(46):17426-31.
    View in: PubMed
  39. Arango NA, Huang TT, Fujino A, Pieretti-Vanmarcke R, Donahoe PK. Expression analysis and evolutionary conservation of the mouse germ cell-specific D6Mm5e gene. Dev Dyn. 2006 Sep; 235(9):2613-9.
    View in: PubMed
  40. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R, Dombkowski D, Preffer F, Maclaughlin DT, Donahoe PK. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci U S A. 2006 Jul 25; 103(30):11154-9.
    View in: PubMed
  41. Tran TT, Segev DL, Gupta V, Kawakubo H, Yeo G, Donahoe PK, Maheswaran S. Mullerian inhibiting substance regulates androgen-induced gene expression and growth in prostate cancer cells through a nuclear factor-kappaB-dependent Smad-independent mechanism. Mol Endocrinol. 2006 Oct; 20(10):2382-91.
    View in: PubMed
  42. Fallat ME, Donahoe PK. Intersex genetic anomalies with malignant potential. Curr Opin Pediatr. 2006 Jun; 18(3):305-11.
    View in: PubMed
  43. Zhan Y, Fujino A, MacLaughlin DT, Manganaro TF, Szotek PP, Arango NA, Teixeira J, Donahoe PK. Müllerian inhibiting substance regulates its receptor/SMAD signaling and causes mesenchymal transition of the coelomic epithelial cells early in Müllerian duct regression. Development. 2006 Jun; 133(12):2359-69.
    View in: PubMed
  44. Donahoe PK. Genomic approaches to surgical diseases: 21st annual Samuel Jason Mixter lecture. Arch Surg. 2006 Apr; 141(4):409-13.
    View in: PubMed
  45. Pieretti-Vanmarcke R, Donahoe PK, Szotek P, Manganaro T, Lorenzen MK, Lorenzen J, Connolly DC, Halpern EF, MacLaughlin DT. Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo. Clin Cancer Res. 2006 Mar 1; 12(5):1593-8.
    View in: PubMed
  46. Kantarci S, Casavant D, Prada C, Russell M, Byrne J, Haug LW, Jennings R, Manning S, Blaise F, Boyd TK, Fryns JP, Holmes LB, Donahoe PK, Lee C, Kimonis V, Pober BR. Findings from aCGH in patients with congenital diaphragmatic hernia (CDH): a possible locus for Fryns syndrome. Am J Med Genet A. 2006 Jan 1; 140(1):17-23.
    View in: PubMed
  47. Kling DE, Brandon KL, Sollinger CA, Cavicchio AJ, Ge Q, Kinane TB, Donahoe PK, Schnitzer JJ. Distribution of ERK1/2 and ERK3 during normal rat fetal lung development. Anat Embryol (Berl). 2006 Mar; 211(2):139-53.
    View in: PubMed
  48. Wang PY, Koishi K, McGeachie AB, Kimber M, Maclaughlin DT, Donahoe PK, McLennan IS. Mullerian inhibiting substance acts as a motor neuron survival factor in vitro. Proc Natl Acad Sci U S A. 2005 Nov 8; 102(45):16421-5.
    View in: PubMed
  49. Arango NA, Szotek PP, Manganaro TF, Oliva E, Donahoe PK, Teixeira J. Conditional deletion of beta-catenin in the mesenchyme of the developing mouse uterus results in a switch to adipogenesis in the myometrium. Dev Biol. 2005 Dec 1; 288(1):276-83.
    View in: PubMed
  50. Pober BR, Lin A, Russell M, Ackerman KG, Chakravorty S, Strauss B, Westgate MN, Wilson J, Donahoe PK, Holmes LB. Infants with Bochdalek diaphragmatic hernia: sibling precurrence and monozygotic twin discordance in a hospital-based malformation surveillance program. Am J Med Genet A. 2005 Oct 1; 138A(2):81-8.
    View in: PubMed
  51. Klaassens M, van Dooren M, Eussen HJ, Douben H, den Dekker AT, Lee C, Donahoe PK, Galjaard RJ, Goemaere N, de Krijger RR, Wouters C, Wauters J, Oostra BA, Tibboel D, de Klein A. Congenital diaphragmatic hernia and chromosome 15q26: determination of a candidate region by use of fluorescent in situ hybridization and array-based comparative genomic hybridization. Am J Hum Genet. 2005 May; 76(5):877-82.
    View in: PubMed
  52. Gupta V, Carey JL, Kawakubo H, Muzikansky A, Green JE, Donahoe PK, MacLaughlin DT, Maheswaran S. Mullerian inhibiting substance suppresses tumor growth in the C3(1)T antigen transgenic mouse mammary carcinoma model. Proc Natl Acad Sci U S A. 2005 Mar 1; 102(9):3219-24.
    View in: PubMed
  53. Kling DE, Aidlen JT, Fisher JC, Kinane TB, Donahoe PK, Schnitzer JJ. Nitrofen induces a redox-dependent apoptosis associated with increased p38 activity in P19 teratocarcinoma cells. Toxicol In Vitro. 2005 Feb; 19(1):1-10.
    View in: PubMed
  54. Kawaguchi AL, Donahoe PK, Ryan DP. Management and long-term follow-up of patients with types III and IV laryngotracheoesophageal clefts. J Pediatr Surg. 2005 Jan; 40(1):158-64; discussion 164-5.
    View in: PubMed
  55. Renaud EJ, MacLaughlin DT, Oliva E, Rueda BR, Donahoe PK. Endometrial cancer is a receptor-mediated target for Mullerian Inhibiting Substance. Proc Natl Acad Sci U S A. 2005 Jan 4; 102(1):111-6.
    View in: PubMed
  56. Arango NA, Pearson EJ, Donahoe PK, Teixeira J. Genomic structure and expression analysis of the mouse testis-specific ribbon protein (Trib) gene. Gene. 2004 Dec 8; 343(1):221-7.
    View in: PubMed
  57. Stoler JM, Leach NT, Donahoe PK. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 36-2004. A 23-day-old infant with hypospadias and failure to thrive. N Engl J Med. 2004 Nov 25; 351(22):2319-26.
    View in: PubMed
  58. Donahoe PK. Sustained inquiry: in the clinic and at the bench. J Pediatr Surg. 2004 Nov; 39(11):1601-6.
    View in: PubMed
  59. Trbovich AM, Martinelle N, O'Neill FH, Pearson EJ, Donahoe PK, Sluss PM, Teixeira J. Steroidogenic activities in MA-10 Leydig cells are differentially altered by cAMP and Müllerian inhibiting substance. J Steroid Biochem Mol Biol. 2004 Oct; 92(3):199-208.
    View in: PubMed
  60. Iafrate AJ, Feuk L, Rivera MN, Listewnik ML, Donahoe PK, Qi Y, Scherer SW, Lee C. Detection of large-scale variation in the human genome. Nat Genet. 2004 Sep; 36(9):949-51.
    View in: PubMed
  61. MacLaughlin DT, Donahoe PK. Sex determination and differentiation. N Engl J Med. 2004 Jan 22; 350(4):367-78.
    View in: PubMed
  62. Wang T, Donahoe PK. The immunophilin FKBP12: a molecular guardian of the TGF-beta family type I receptors. Front Biosci. 2004 Jan 1; 9:619-31.
    View in: PubMed
  63. Donahoe PK, Clarke T, Teixeira J, Maheswaran S, MacLaughlin DT. Enhanced purification and production of Müllerian inhibiting substance for therapeutic applications. Mol Cell Endocrinol. 2003 Dec 15; 211(1-2):37-42.
    View in: PubMed
  64. Lee MM, Misra M, Donahoe PK, MacLaughlin DT. MIS/AMH in the assessment of cryptorchidism and intersex conditions. Mol Cell Endocrinol. 2003 Dec 15; 211(1-2):91-8.
    View in: PubMed
  65. Barbie TU, Barbie DA, MacLaughlin DT, Maheswaran S, Donahoe PK. Mullerian Inhibiting Substance inhibits cervical cancer cell growth via a pathway involving p130 and p107. Proc Natl Acad Sci U S A. 2003 Dec 23; 100(26):15601-6.
    View in: PubMed
  66. Houk CP, Pearson EJ, Martinelle N, Donahoe PK, Teixeira J. Feedback inhibition of steroidogenic acute regulatory protein expression in vitro and in vivo by androgens. Endocrinology. 2004 Mar; 145(3):1269-75.
    View in: PubMed
  67. Salva A, Hardy MP, Wu XF, Sottas CM, MacLaughlin DT, Donahoe PK, Lee MM. Müllerian-inhibiting substance inhibits rat Leydig cell regeneration after ethylene dimethanesulphonate ablation. Biol Reprod. 2004 Mar; 70(3):600-7.
    View in: PubMed
  68. Hoshiya Y, Gupta V, Kawakubo H, Brachtel E, Carey JL, Sasur L, Scott A, Donahoe PK, Maheswaran S. Mullerian inhibiting substance promotes interferon gamma-induced gene expression and apoptosis in breast cancer cells. J Biol Chem. 2003 Dec 19; 278(51):51703-12.
    View in: PubMed
  69. Hoshiya M, Christian BP, Cromie WJ, Kim H, Zhan Y, MacLaughlin DT, Donahoe PK. Persistent Mullerian duct syndrome caused by both a 27-bp deletion and a novel splice mutation in the MIS type II receptor gene. Birth Defects Res A Clin Mol Teratol. 2003 Oct; 67(10):868-74.
    View in: PubMed
  70. Dasgupta R, Schnitzer JJ, Hendren WH, Donahoe PK. Congenital adrenal hyperplasia: surgical considerations required to repair a 46,XX patient raised as a boy. J Pediatr Surg. 2003 Aug; 38(8):1269-73.
    View in: PubMed
  71. Misra M, MacLaughlin DT, Donahoe PK, Lee MM. The role of Müllerian inhibiting substance in the evaluation of phenotypic female patients with mild degrees of virilization. J Clin Endocrinol Metab. 2003 Feb; 88(2):787-92.
    View in: PubMed
  72. Laurich VM, Trbovich AM, O'Neill FH, Houk CP, Sluss PM, Payne AH, Donahoe PK, Teixeira J. Müllerian inhibiting substance blocks the protein kinase A-induced expression of cytochrome p450 17alpha-hydroxylase/C(17-20) lyase mRNA in a mouse Leydig cell line independent of cAMP responsive element binding protein phosphorylation. Endocrinology. 2002 Sep; 143(9):3351-60.
    View in: PubMed
  73. Misra M, MacLaughlin DT, Donahoe PK, Lee MM. Measurement of Mullerian inhibiting substance facilitates management of boys with microphallus and cryptorchidism. J Clin Endocrinol Metab. 2002 Aug; 87(8):3598-602.
    View in: PubMed
  74. Stephen AE, Pearsall LA, Christian BP, Donahoe PK, Vacanti JP, MacLaughlin DT. Highly purified müllerian inhibiting substance inhibits human ovarian cancer in vivo. Clin Cancer Res. 2002 Aug; 8(8):2640-6.
    View in: PubMed
  75. Kling DE, Lorenzo HK, Trbovich AM, Kinane TB, Donahoe PK, Schnitzer JJ. MEK-1/2 inhibition reduces branching morphogenesis and causes mesenchymal cell apoptosis in fetal rat lungs. Am J Physiol Lung Cell Mol Physiol. 2002 Mar; 282(3):L370-8.
    View in: PubMed
  76. Lorenzo HK, Teixeira J, Pahlavan N, Laurich VM, Donahoe PK, MacLaughlin DT. New approaches for high-yield purification of Müllerian inhibiting substance improve its bioactivity. J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Jan 5; 766(1):89-98.
    View in: PubMed
  77. Segev DL, Hoshiya Y, Hoshiya M, Tran TT, Carey JL, Stephen AE, MacLaughlin DT, Donahoe PK, Maheswaran S. Mullerian-inhibiting substance regulates NF-kappa B signaling in the prostate in vitro and in vivo. Proc Natl Acad Sci U S A. 2002 Jan 8; 99(1):239-44.
    View in: PubMed
  78. MacLaughlin DT, Donahoe PK. Mullerian inhibiting substance: an update. Adv Exp Med Biol. 2002; 511:25-38; discussion 38-40.
    View in: PubMed
  79. Teixeira J, Maheswaran S, Donahoe PK. Müllerian inhibiting substance: an instructive developmental hormone with diagnostic and possible therapeutic applications. Endocr Rev. 2001 Oct; 22(5):657-74.
    View in: PubMed
  80. Kling DE, Narra V, Islam S, Kinane TB, Alessandrini A, Ercolani L, Donahoe PK, Schnitzer JJ. Decreased mitogen activated protein kinase activities in congenital diaphragmatic hernia-associated pulmonary hypoplasia. J Pediatr Surg. 2001 Oct; 36(10):1490-6.
    View in: PubMed
  81. Sriraman V, Niu E, Matias JR, Donahoe PK, MacLaughlin DT, Hardy MP, Lee MM. Müllerian inhibiting substance inhibits testosterone synthesis in adult rats. J Androl. 2001 Sep-Oct; 22(5):750-8.
    View in: PubMed
  82. Clarke TR, Hoshiya Y, Yi SE, Liu X, Lyons KM, Donahoe PK. Müllerian inhibiting substance signaling uses a bone morphogenetic protein (BMP)-like pathway mediated by ALK2 and induces SMAD6 expression. Mol Endocrinol. 2001 Jun; 15(6):946-59.
    View in: PubMed
  83. MacLaughlin DT, Teixeira J, Donahoe PK. Perspective: reproductive tract development--new discoveries and future directions. Endocrinology. 2001 Jun; 142(6):2167-72.
    View in: PubMed
  84. Segev DL, Hoshiya Y, Stephen AE, Hoshiya M, Tran TT, MacLaughlin DT, Donahoe PK, Maheswaran S. Mullerian inhibiting substance regulates NFkappaB signaling and growth of mammary epithelial cells in vivo. J Biol Chem. 2001 Jul 20; 276(29):26799-806.
    View in: PubMed
  85. Trbovich AM, Sluss PM, Laurich VM, O'Neill FH, MacLaughlin DT, Donahoe PK, Teixeira J. Müllerian Inhibiting Substance lowers testosterone in luteinizing hormone-stimulated rodents. Proc Natl Acad Sci U S A. 2001 Mar 13; 98(6):3393-7.
    View in: PubMed
  86. Schnitzer JJ, Donahoe PK. Surgical treatment of congenital adrenal hyperplasia. Endocrinol Metab Clin North Am. 2001 Mar; 30(1):137-54.
    View in: PubMed
  87. Ukiyama E, Jancso-Radek A, Li B, Milos L, Zhang W, Phillips NB, Morikawa N, King CY, Chan G, Haqq CM, Radek JT, Poulat F, Donahoe PK, Weiss MA. SRYand architectural gene regulation: the kinetic stability of a bent protein-DNA complex can regulate its transcriptional potency. Mol Endocrinol. 2001 Mar; 15(3):363-77.
    View in: PubMed
  88. Stephen AE, Masiakos PT, Segev DL, Vacanti JP, Donahoe PK, MacLaughlin DT. Tissue-engineered cells producing complex recombinant proteins inhibit ovarian cancer in vivo. Proc Natl Acad Sci U S A. 2001 Mar 13; 98(6):3214-9.
    View in: PubMed
  89. Ha TU, Segev DL, Barbie D, Masiakos PT, Tran TT, Dombkowski D, Glander M, Clarke TR, Lorenzo HK, Donahoe PK, Maheswaran S. Mullerian inhibiting substance inhibits ovarian cell growth through an Rb-independent mechanism. J Biol Chem. 2000 Nov 24; 275(47):37101-9.
    View in: PubMed
  90. Morikawa N, Clarke TR, Novina CD, Watanabe K, Haqq C, Weiss M, Roy AL, Donahoe PK. Human Müllerian-inhibiting substance promoter contains a functional TFII-I-binding initiator. Biol Reprod. 2000 Oct; 63(4):1075-83.
    View in: PubMed
  91. Segev DL, Ha TU, Tran TT, Kenneally M, Harkin P, Jung M, MacLaughlin DT, Donahoe PK, Maheswaran S. Mullerian inhibiting substance inhibits breast cancer cell growth through an NFkappa B-mediated pathway. J Biol Chem. 2000 Sep 15; 275(37):28371-9.
    View in: PubMed
  92. Oh SP, Seki T, Goss KA, Imamura T, Yi Y, Donahoe PK, Li L, Miyazono K, ten Dijke P, Kim S, Li E. Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. Proc Natl Acad Sci U S A. 2000 Mar 14; 97(6):2626-31.
    View in: PubMed
  93. Watanabe K, Clarke TR, Lane AH, Wang X, Donahoe PK. Endogenous expression of Müllerian inhibiting substance in early postnatal rat sertoli cells requires multiple steroidogenic factor-1 and GATA-4-binding sites. Proc Natl Acad Sci U S A. 2000 Feb 15; 97(4):1624-9.
    View in: PubMed
  94. McSweeney FK, Donahoe P, Swindell S. Women in applied behavior analysis. Behav Anal. 2000; 23(2):267-77.
    View in: PubMed
  95. Teixeira J, Kehas DJ, Antun R, Donahoe PK. Transcriptional regulation of the rat Müllerian inhibiting substance type II receptor in rodent Leydig cells. Proc Natl Acad Sci U S A. 1999 Nov 23; 96(24):13831-8.
    View in: PubMed
  96. Masiakos PT, MacLaughlin DT, Maheswaran S, Teixeira J, Fuller AF, Shah PC, Kehas DJ, Kenneally MK, Dombkowski DM, Ha TU, Preffer FI, Donahoe PK. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS. Clin Cancer Res. 1999 Nov; 5(11):3488-99.
    View in: PubMed
  97. Teixeira J, Fynn-Thompson E, Payne AH, Donahoe PK. Müllerian-inhibiting substance regulates androgen synthesis at the transcriptional level. Endocrinology. 1999 Oct; 140(10):4732-8.
    View in: PubMed
  98. Islam S, Donahoe PK, Schnitzer JJ. Tracheal ligation increases mitogen-activated protein kinase activity and attenuates surfactant protein B mRNA in fetal sheep lungs. J Surg Res. 1999 Jun 1; 84(1):19-23.
    View in: PubMed
  99. Lee MM, Seah CC, Masiakos PT, Sottas CM, Preffer FI, Donahoe PK, Maclaughlin DT, Hardy MP. Müllerian-inhibiting substance type II receptor expression and function in purified rat Leydig cells. Endocrinology. 1999 Jun; 140(6):2819-27.
    View in: PubMed
  100. Gu Z, Reynolds EM, Song J, Lei H, Feijen A, Yu L, He W, MacLaughlin DT, van den Eijnden-van Raaij J, Donahoe PK, Li E. The type I serine/threonine kinase receptor ActRIA (ALK2) is required for gastrulation of the mouse embryo. Development. 1999 Jun; 126(11):2551-61.
    View in: PubMed
  101. Lane AH, Lee MM, Fuller AF, Kehas DJ, Donahoe PK, MacLaughlin DT. Diagnostic utility of Müllerian inhibiting substance determination in patients with primary and recurrent granulosa cell tumors. Gynecol Oncol. 1999 Apr; 73(1):51-5.
    View in: PubMed
  102. Morita Y, Manganaro TF, Tao XJ, Martimbeau S, Donahoe PK, Tilly JL. Requirement for phosphatidylinositol-3'-kinase in cytokine-mediated germ cell survival during fetal oogenesis in the mouse. Endocrinology. 1999 Feb; 140(2):941-9.
    View in: PubMed
  103. Islam S, Narra V, Coté GM, Manganaro TF, Donahoe PK, Schnitzer JJ. Prenatal vitamin E treatment improves lung growth in fetal rats with congenital diaphragmatic hernia. J Pediatr Surg. 1999 Jan; 34(1):172-6 discussion 176-7.
    View in: PubMed
  104. Lane AH, Donahoe PK. New insights into mullerian inhibiting substance and its mechanism of action. J Endocrinol. 1998 Jul; 158(1):1-6.
    View in: PubMed
  105. Gu Z, Nomura M, Simpson BB, Lei H, Feijen A, van den Eijnden-van Raaij J, Donahoe PK, Li E. The type I activin receptor ActRIB is required for egg cylinder organization and gastrulation in the mouse. Genes Dev. 1998 Mar 15; 12(6):844-57.
    View in: PubMed
  106. Losty PD, Vanamo K, Rintala RJ, Donahoe PK, Schnitzer JJ, Lloyd DA. Congenital diaphragmatic hernia--does the side of the defect influence the incidence of associated malformations? J Pediatr Surg. 1998 Mar; 33(3):507-10.
    View in: PubMed
  107. Haqq CM, Donahoe PK. Regulation of sexual dimorphism in mammals. Physiol Rev. 1998 Jan; 78(1):1-33.
    View in: PubMed
  108. Masiakos PT, Flynn CE, Donahoe PK. Masculinizing and feminizing syndromes caused by functioning tumors. Semin Pediatr Surg. 1997 Aug; 6(3):147-55.
    View in: PubMed
  109. Ijsselstijn H, Pacheco BA, Albert A, Sluiter W, Donahoe PK, De Jongste JC, Schnitzer JJ, Tibboel D. Prenatal hormones alter antioxidant enzymes and lung histology in rats with congenital diaphragmatic hernia. Am J Physiol. 1997 Jun; 272(6 Pt 1):L1059-65.
    View in: PubMed
  110. Lee MM, Donahoe PK, Silverman BL, Hasegawa T, Hasegawa Y, Gustafson ML, Chang YC, MacLaughlin DT. Measurements of serum müllerian inhibiting substance in the evaluation of children with nonpalpable gonads. N Engl J Med. 1997 May 22; 336(21):1480-6.
    View in: PubMed
  111. Catlin EA, Tonnu VC, Ebb RG, Pacheco BA, Manganaro TF, Ezzell RM, Donahoe PK, Teixeira J. Müllerian inhibiting substance inhibits branching morphogenesis and induces apoptosis in fetal rat lung. Endocrinology. 1997 Feb; 138(2):790-6.
    View in: PubMed
  112. Hedrick HL, Kaban JM, Pacheco BA, Losty PD, Doody DP, Ryan DP, Manganaro TF, Donahoe PK, Schnitzer JJ. Prenatal glucocorticoids improve pulmonary morphometrics in fetal sheep with congenital diaphragmatic hernia. J Pediatr Surg. 1997 Feb; 32(2):217-21; discussion 221-2.
    View in: PubMed
  113. Lee MM, Donahoe PK. The infant with ambiguous genitalia. Curr Ther Endocrinol Metab. 1997; 6:216-23.
    View in: PubMed
  114. Kluth D, Losty PD, Schnitzer JJ, Lambrecht W, Donahoe PK. Toward understanding the developmental anatomy of congenital diaphragmatic hernia. Clin Perinatol. 1996 Dec; 23(4):655-69.
    View in: PubMed
  115. Schnitzer JJ, Hedrick HL, Pacheco BA, Losty PD, Ryan DP, Doody DP, Donahoe PK. Prenatal glucocorticoid therapy reverses pulmonary immaturity in congenital diaphragmatic hernia in fetal sheep. Ann Surg. 1996 Oct; 224(4):430-7; discussion 437-9.
    View in: PubMed
  116. Losty PD, Pacheco BA, Manganaro TF, Donahoe PK, Jones RC, Schnitzer JJ. Prenatal hormonal therapy improves pulmonary morphology in rats with congenital diaphragmatic hernia. J Surg Res. 1996 Sep; 65(1):42-52.
    View in: PubMed
  117. Wang T, Li BY, Danielson PD, Shah PC, Rockwell S, Lechleider RJ, Martin J, Manganaro T, Donahoe PK. The immunophilin FKBP12 functions as a common inhibitor of the TGF beta family type I receptors. Cell. 1996 Aug 9; 86(3):435-44.
    View in: PubMed
  118. Simpson BB, Ryan DP, Donahoe PK, Schnitzer JJ, Kim SH, Doody DP. Type IV laryngotracheoesophageal clefts: surgical management for long-term survival. J Pediatr Surg. 1996 Aug; 31(8):1128-33.
    View in: PubMed
  119. Shah PC, Simpson BB, Donahoe PK. Müllerian inhibiting substance as a model for the transforming growth factor-beta family: development of new treatment strategies. Semin Pediatr Surg. 1996 Aug; 5(3):182-90.
    View in: PubMed
  120. Teixeira J, Donahoe PK. Molecular biology of MIS and its receptors. J Androl. 1996 Jul-Aug; 17(4):336-41.
    View in: PubMed
  121. Wang T, Danielson PD, Li BY, Shah PC, Kim SD, Donahoe PK. The p21(RAS) farnesyltransferase alpha subunit in TGF-beta and activin signaling. Science. 1996 Feb 23; 271(5252):1120-2.
    View in: PubMed
  122. Maggard MA, Catlin EA, Hudson PL, Donahoe PK, MacLaughlin DT. Reduction of epidermal growth factor receptor phosphorylation by activated Mullerian inhibiting substance is vanadate-sensitive. Metabolism. 1996 Feb; 45(2):190-5.
    View in: PubMed
  123. Lee MM, Donahoe PK, Hasegawa T, Silverman B, Crist GB, Best S, Hasegawa Y, Noto RA, Schoenfeld D, MacLaughlin DT. Mullerian inhibiting substance in humans: normal levels from infancy to adulthood. J Clin Endocrinol Metab. 1996 Feb; 81(2):571-6.
    View in: PubMed
  124. Donahoe PK, Schnitzer JJ. Evaluation of the infant who has ambiguous genitalia, and principles of operative management. Semin Pediatr Surg. 1996 Feb; 5(1):30-40.
    View in: PubMed
  125. Teixeira J, He WW, Shah PC, Morikawa N, Lee MM, Catlin EA, Hudson PL, Wing J, Maclaughlin DT, Donahoe PK. Developmental expression of a candidate müllerian inhibiting substance type II receptor. Endocrinology. 1996 Jan; 137(1):160-5.
    View in: PubMed
  126. Peters R, King CY, Ukiyama E, Falsafi S, Donahoe PK, Weiss MA. An SRY mutation causing human sex reversal resolves a general mechanism of structure-specific DNA recognition: application to the four-way DNA junction. Biochemistry. 1995 Apr 11; 34(14):4569-76.
    View in: PubMed
  127. Losty PD, Suen HC, Manganaro TF, Donahoe PK, Schnitzer JJ. Prenatal hormonal therapy improves pulmonary compliance in the nitrofen-induced CDH rat model. J Pediatr Surg. 1995 Mar; 30(3):420-6.
    View in: PubMed
  128. Kurian MS, de la Cuesta RS, Waneck GL, MacLaughlin DT, Manganaro TF, Donahoe PK. Cleavage of Müllerian inhibiting substance activates antiproliferative effects in vivo. Clin Cancer Res. 1995 Mar; 1(3):343-9.
    View in: PubMed
  129. Alles AJ, Losty PD, Donahoe PK, Manganaro TF, Schnitzer JJ. Embryonic cell death patterns associated with nitrofen-induced congenital diaphragmatic hernia. J Pediatr Surg. 1995 Feb; 30(2):353-8; discussion 359-60.
    View in: PubMed
  130. O'Neill JA, Cnaan A, Altman RP, Donahoe PK, Holder TM, Neblett WW, Schwartz MZ, Smith CD. Update on the analysis of the need for pediatric surgeons in the United States. J Pediatr Surg. 1995 Feb; 30(2):204-10; discussion 211-3.
    View in: PubMed
  131. Federman DD, Donahoe PK. Ambiguous genitalia--etiology, diagnosis, and therapy. Adv Endocrinol Metab. 1995; 6:91-116.
    View in: PubMed
  132. Haqq CM, King CY, Ukiyama E, Falsafi S, Haqq TN, Donahoe PK, Weiss MA. Molecular basis of mammalian sexual determination: activation of Müllerian inhibiting substance gene expression by SRY. Science. 1994 Dec 2; 266(5190):1494-500.
    View in: PubMed
  133. Meyers-Wallen VN, MacLaughlin D, Palmer V, Donahoe PK. Mullerian-inhibiting substance secretion is delayed in XX sex-reversed dog embryos. Mol Reprod Dev. 1994 Sep; 39(1):1-7.
    View in: PubMed
  134. Hudson PL, Pedersen WA, Saltsman WS, Liscovitch M, MacLaughlin DT, Donahoe PK, Blusztajn JK. Modulation by sphingolipids of calcium signals evoked by epidermal growth factor. J Biol Chem. 1994 Aug 26; 269(34):21885-90.
    View in: PubMed
  135. Suen HC, Losty PD, Donahoe PK, Schnitzer JJ. Accurate method to study static volume-pressure relationships in small fetal and neonatal animals. J Appl Physiol. 1994 Aug; 77(2):1036-43.
    View in: PubMed
  136. Wang T, Donahoe PK, Zervos AS. Specific interaction of type I receptors of the TGF-beta family with the immunophilin FKBP-12. Science. 1994 Jul 29; 265(5172):674-6.
    View in: PubMed
  137. Hirobe S, He WW, Gustafson ML, MacLaughlin DT, Donahoe PK. Müllerian inhibiting substance gene expression in the cycling rat ovary correlates with recruited or graafian follicle selection. Biol Reprod. 1994 Jun; 50(6):1238-43.
    View in: PubMed
  138. Bassing CH, Howe DJ, Segarini PR, Donahoe PK, Wang XF. A single heteromeric receptor complex is sufficient to mediate biological effects of transforming growth factor-beta ligands. J Biol Chem. 1994 May 27; 269(21):14861-4.
    View in: PubMed
  139. Suen HC, Bloch KD, Donahoe PK. Antenatal glucocorticoid corrects pulmonary immaturity in experimentally induced congenital diaphragmatic hernia in rats. Pediatr Res. 1994 May; 35(5):523-9.
    View in: PubMed
  140. Lee MM, Gustafson ML, Ukiyama E, Donahoe PK, MacLaughlin DT, Wexler M, Keeping HS. Developmental changes in mullerian inhibiting substance in the cynomolgus monkey, Macaca fascicularis. J Clin Endocrinol Metab. 1994 Mar; 78(3):615-21.
    View in: PubMed
  141. Donahoe PK, Gustafson ML. Early one-stage surgical reconstruction of the extremely high vagina in patients with congenital adrenal hyperplasia. J Pediatr Surg. 1994 Feb; 29(2):352-8.
    View in: PubMed
  142. Suen HC, Losty P, Donahoe PK, Schnitzer JJ. Combined antenatal thyrotropin-releasing hormone and low-dose glucocorticoid therapy improves the pulmonary biochemical immaturity in congenital diaphragmatic hernia. J Pediatr Surg. 1994 Feb; 29(2):359-63.
    View in: PubMed
  143. Bassing CH, Yingling JM, Howe DJ, Wang T, He WW, Gustafson ML, Shah P, Donahoe PK, Wang XF. A transforming growth factor beta type I receptor that signals to activate gene expression. Science. 1994 Jan 7; 263(5143):87-9.
    View in: PubMed
  144. Gustafson ML, Donahoe PK. Male sex determination: current concepts of male sexual differentiation. Annu Rev Med. 1994; 45:505-24.
    View in: PubMed
  145. Lee MM, Donahoe PK. Ambiguous genitalia. Curr Ther Endocrinol Metab. 1994; 5:242-9.
    View in: PubMed
  146. Catlin EA, Ezzell RM, Donahoe PK, Gustafson ML, Son EV, MacLaughlin DT. Identification of a receptor for human müllerian inhibiting substance. Endocrinology. 1993 Dec; 133(6):3007-13.
    View in: PubMed
  147. Taketo T, Saeed J, Manganaro T, Takahashi M, Donahoe PK. Müllerian inhibiting substance production associated with loss of oocytes and testicular differentiation in the transplanted mouse XX gonadal primordium. Biol Reprod. 1993 Jul; 49(1):13-23.
    View in: PubMed
  148. Catlin EA, MacLaughlin DT, Donahoe PK. Müllerian inhibiting substance: new perspectives and future directions. Microsc Res Tech. 1993 Jun 1; 25(2):121-33.
    View in: PubMed
  149. Meyers-Wallen VN, Lee MM, Manganaro TF, Kuroda T, Maclaughlin D, Donahoe PK. Müllerian inhibiting substance is present in embryonic testes of dogs with persistent müllerian duct syndrome. Biol Reprod. 1993 Jun; 48(6):1410-8.
    View in: PubMed
  150. Lee MM, Donahoe PK. Mullerian inhibiting substance: a gonadal hormone with multiple functions. Endocr Rev. 1993 Apr; 14(2):152-64.
    View in: PubMed
  151. Suen HC, Catlin EA, Ryan DP, Wain JC, Donahoe PK. Biochemical immaturity of lungs in congenital diaphragmatic hernia. J Pediatr Surg. 1993 Mar; 28(3):471-5; discussion 476-7.
    View in: PubMed
  152. Seifer DB, MacLaughlin DT, Penzias AS, Behrman HR, Asmundson L, Donahoe PK, Haning RV, Flynn SD. Gonadotropin-releasing hormone agonist-induced differences in granulosa cell cycle kinetics are associated with alterations in follicular fluid müllerian-inhibiting substance and androgen content. J Clin Endocrinol Metab. 1993 Mar; 76(3):711-4.
    View in: PubMed
  153. Gustafson ML, Lee MM, Asmundson L, MacLaughlin DT, Donahoe PK. Müllerian inhibiting substance in the diagnosis and management of intersex and gonadal abnormalities. J Pediatr Surg. 1993 Mar; 28(3):439-44.
    View in: PubMed
  154. Boveri J, Parry R, Ruffin W, Gustafson M, Lee K, He W, Donahoe P. Transfection of the mullerian inhibiting substance gene inhibits local and metastatic tumor-growth. Int J Oncol. 1993 Feb; 2(2):135-43.
    View in: PubMed
  155. Haqq CM, King CY, Donahoe PK, Weiss MA. SRY recognizes conserved DNA sites in sex-specific promoters. Proc Natl Acad Sci U S A. 1993 Feb 1; 90(3):1097-101.
    View in: PubMed
  156. He WW, Gustafson ML, Hirobe S, Donahoe PK. Developmental expression of four novel serine/threonine kinase receptors homologous to the activin/transforming growth factor-beta type II receptor family. Dev Dyn. 1993 Feb; 196(2):133-42.
    View in: PubMed
  157. MacLaughlin DT, Levin RK, Catlin EA, Taylor LA, Preffer FI, Donahoe PK. Identification of müllerian inhibiting substance specific binding in human cell lines. Horm Metab Res. 1992 Dec; 24(12):570-5.
    View in: PubMed
  158. Kim JH, Seibel MM, MacLaughlin DT, Donahoe PK, Ransil BJ, Hametz PA, Richards CJ. The inhibitory effects of müllerian-inhibiting substance on epidermal growth factor induced proliferation and progesterone production of human granulosa-luteal cells. J Clin Endocrinol Metab. 1992 Sep; 75(3):911-7.
    View in: PubMed
  159. Tsuji M, Shima H, Yonemura CY, Brody J, Donahoe PK, Cunha GR. Effect of human recombinant mullerian inhibiting substance on isolated epithelial and mesenchymal cells during mullerian duct regression in the rat. Endocrinology. 1992 Sep; 131(3):1481-8.
    View in: PubMed
  160. Dumanian GA, Donahoe PK. Bilateral rotated buttock flaps for vaginal atresia in severely masculinized females with adrenogenital syndrome. Plast Reconstr Surg. 1992 Sep; 90(3):487-91.
    View in: PubMed
  161. Hirobe S, He WW, Lee MM, Donahoe PK. Mullerian inhibiting substance messenger ribonucleic acid expression in granulosa and Sertoli cells coincides with their mitotic activity. Endocrinology. 1992 Aug; 131(2):854-62.
    View in: PubMed
  162. MacLaughlin DT, Hudson PL, Graciano AL, Kenneally MK, Ragin RC, Manganaro TF, Donahoe PK. Mullerian duct regression and antiproliferative bioactivities of mullerian inhibiting substance reside in its carboxy-terminal domain. Endocrinology. 1992 Jul; 131(1):291-6.
    View in: PubMed
  163. Ragin RC, Donahoe PK, Kenneally MK, Ahmad MF, MacLaughlin DT. Human müllerian inhibiting substance: enhanced purification imparts biochemical stability and restores antiproliferative effects. Protein Expr Purif. 1992 Jun; 3(3):236-45.
    View in: PubMed
  164. Donahoe PK. Müllerian inhibiting substance in reproduction and cancer. Mol Reprod Dev. 1992 Jun; 32(2):168-72.
    View in: PubMed
  165. Catlin EA, Ezzell RM, Donahoe PK, Manganaro TF, Ebb RG, MacLaughlin DT. Mullerian inhibiting substance binding and uptake. Dev Dyn. 1992 Apr; 193(4):295-9.
    View in: PubMed
  166. Haqq C, Lee MM, Tizard R, Wysk M, DeMarinis J, Donahoe PK, Cate RL. Isolation of the rat gene for Mullerian inhibiting substance. Genomics. 1992 Apr; 12(4):665-9.
    View in: PubMed
  167. Schreiber RA, Kleinman RE, Barksdale EM, Maganaro TF, Donahoe PK. Rejection of murine congenic bile ducts: a model for immune-mediated bile duct disease. Gastroenterology. 1992 Mar; 102(3):924-30.
    View in: PubMed
  168. Parry RL, Chin TW, Epstein J, Hudson PL, Powell DM, Donahoe PK. Recombinant human mullerian inhibiting substance inhibits human ocular melanoma cell lines in vitro and in vivo. Cancer Res. 1992 Mar 1; 52(5):1182-6.
    View in: PubMed
  169. Hirobe S, Doody DP, Ryan DP, Kim SH, Donahoe PK. Ectopic class II major histocompatibility antigens in Hirschsprung's disease and neuronal intestinal dysplasia. J Pediatr Surg. 1992 Mar; 27(3):357-62; discussion 363.
    View in: PubMed
  170. Gustafson ML, Lee MM, Scully RE, Moncure AC, Hirakawa T, Goodman A, Muntz HG, Donahoe PK, MacLaughlin DT, Fuller AF. Müllerian inhibiting substance as a marker for ovarian sex-cord tumor. N Engl J Med. 1992 Feb 13; 326(7):466-71.
    View in: PubMed
  171. Lee MM, Cate RL, Donahoe PK, Waneck GL. Developmentally regulated polyadenylation of two discrete messenger ribonucleic acids for müllerian inhibiting substance. Endocrinology. 1992 Feb; 130(2):847-53.
    View in: PubMed
  172. Kuroda T, Lee MM, Ragin RC, Hirobe S, Donahoe PK. Müllerian inhibiting substance production and cleavage is modulated by gonadotropins and steroids. Endocrinology. 1991 Dec; 129(6):2985-92.
    View in: PubMed
  173. Catlin EA, Uitvlugt ND, Donahoe PK, Powell DM, Hayashi M, MacLaughlin DT. Müllerian inhibiting substance blocks epidermal growth factor receptor phosphorylation in fetal rat lung membranes. Metabolism. 1991 Nov; 40(11):1178-84.
    View in: PubMed
  174. Meyers-Wallen VN, Manganaro TF, Kuroda T, Concannon PW, MacLaughlin DT, Donahoe PK. The critical period for mullerian duct regression in the dog embryo. Biol Reprod. 1991 Oct; 45(4):626-33.
    View in: PubMed
  175. Taketo T, Saeed J, Nishioka Y, Donahoe PK. Delay of testicular differentiation in the B6.YDOM ovotestis demonstrated by immunocytochemical staining for müllerian inhibiting substance. Dev Biol. 1991 Aug; 146(2):386-95.
    View in: PubMed
  176. Donahoe PK, Powell DM, Lee MM. Clinical management of intersex abnormalities. Curr Probl Surg. 1991 Aug; 28(8):513-79.
    View in: PubMed
  177. Ryan DP, Muehrcke DD, Doody DP, Kim SH, Donahoe PK. Laryngotracheoesophageal cleft (type IV): management and repair of lesions beyond the carina. J Pediatr Surg. 1991 Aug; 26(8):962-9; discussion 969-70.
    View in: PubMed
  178. Barksdale EM, McGenis TG, Donahoe PK. Gonadotropins moderate rejection of trophic-specific congenic testes grafts. J Pediatr Surg. 1991 Aug; 26(8):886-92.
    View in: PubMed
  179. Parry RL, Chin TW, Donahoe PK. Computer-aided cell colony counting. Biotechniques. 1991 Jun; 10(6):772-4.
    View in: PubMed
  180. Kuroda T, Doody DP, Donahoe PK. Aberrant colonic expression of MHC class II antigens in Hirschsprung's disease. Aust N Z J Surg. 1991 May; 61(5):373-9.
    View in: PubMed
  181. Chin TW, Parry RL, Donahoe PK. Human müllerian inhibiting substance inhibits tumor growth in vitro and in vivo. Cancer Res. 1991 Apr 15; 51(8):2101-6.
    View in: PubMed
  182. MacLaughlin DT, Epstein J, Donahoe PK. Bioassay, purification, cloning, and expression of müllerian inhibiting substance. Methods Enzymol. 1991; 198:358-69.
    View in: PubMed
  183. Epstein J, Lee MM, Kelly CE, Donahoe PK. Effect of E. coli endotoxin on mammalian cell growth and recombinant protein production. In Vitro Cell Dev Biol. 1990 Dec; 26(12):1121-2.
    View in: PubMed
  184. Dershewitz R, Gallagher SS, Donahoe P. Sledding-related injuries in children. Am J Dis Child. 1990 Oct; 144(10):1071-3.
    View in: PubMed
  185. Kuroda T, Lee MM, Haqq CM, Powell DM, Manganaro TF, Donahoe PK. Mullerian inhibiting substance ontogeny and its modulation by follicle-stimulating hormone in the rat testes. Endocrinology. 1990 Oct; 127(4):1825-32.
    View in: PubMed
  186. Catlin EA, Powell SM, Manganaro TF, Hudson PL, Ragin RC, Epstein J, Donahoe PK. Sex-specific fetal lung development and müllerian inhibiting substance. Am Rev Respir Dis. 1990 Feb; 141(2):466-70.
    View in: PubMed
  187. Hudson PL, Dougas I, Donahoe PK, Cate RL, Epstein J, Pepinsky RB, MacLaughlin DT. An immunoassay to detect human müllerian inhibiting substance in males and females during normal development. J Clin Endocrinol Metab. 1990 Jan; 70(1):16-22.
    View in: PubMed
  188. Meyers-Wallen VN, Donahoe PK, Ueno S, Manganaro TF, Patterson DF. Müllerian inhibiting substance is present in testes of dogs with persistent müllerian duct syndrome. Biol Reprod. 1989 Nov; 41(5):881-8.
    View in: PubMed
  189. Ueno S, Kuroda T, Maclaughlin DT, Ragin RC, Manganaro TF, Donahoe PK. Mullerian inhibiting substance in the adult rat ovary during various stages of the estrous cycle. Endocrinology. 1989 Aug; 125(2):1060-6.
    View in: PubMed
  190. Wallen JW, Cate RL, Kiefer DM, Riemen MW, Martinez D, Hoffman RM, Donahoe PK, Von Hoff DD, Pepinsky B, Oliff A. Minimal antiproliferative effect of recombinant müllerian inhibiting substance on gynecological tumor cell lines and tumor explants. Cancer Res. 1989 Apr 15; 49(8):2005-11.
    View in: PubMed
  191. Statter MB, Fahrner KJ, Barksdale EM, Parks DE, Flavell RA, Donahoe PK. Correlation of fetal kidney and testis congenic graft survival with reduced major histocompatibility complex burden. Transplantation. 1989 Apr; 47(4):651-60.
    View in: PubMed
  192. Epstein J, Desjardins EJ, Hudson PL, Donahoe PK. Stainless steel mesh supports high density cell growth and production of recombinant müllerian inhibiting substances. In Vitro Cell Dev Biol. 1989 Feb; 25(2):213-6.
    View in: PubMed
  193. Ueno S, Takahashi M, Manganaro TF, Ragin RC, Donahoe PK. Cellular localization of müllerian inhibiting substance in the developing rat ovary. Endocrinology. 1989 Feb; 124(2):1000-6.
    View in: PubMed
  194. Cigarroa FG, Coughlin JP, Donahoe PK, White MF, Uitvlugt N, MacLaughlin DT. Recombinant human müllerian inhibiting substance inhibits epidermal growth factor receptor tyrosine kinase. Growth Factors. 1989; 1(2):179-91.
    View in: PubMed
  195. Pepinsky RB, Sinclair LK, Chow EP, Mattaliano RJ, Manganaro TF, Donahoe PK, Cate RL. Proteolytic processing of mullerian inhibiting substance produces a transforming growth factor-beta-like fragment. J Biol Chem. 1988 Dec 15; 263(35):18961-4.
    View in: PubMed
  196. Catlin EA, Manganaro TF, Donahoe PK. Müllerian inhibiting substance depresses accumulation in vitro of disaturated phosphatidylcholine in fetal rat lung. Am J Obstet Gynecol. 1988 Nov; 159(5):1299-303.
    View in: PubMed
  197. Ueno S, Manganaro TF, Donahoe PK. Human recombinant mullerian inhibiting substance inhibition of rat oocyte meiosis is reversed by epidermal growth factor in vitro. Endocrinology. 1988 Sep; 123(3):1652-9.
    View in: PubMed
  198. Coughlin JP, Cigarroa F, Donahoe PK, McLaughlin DT. Human recombinant mullerian inhibiting substance inhibits epidermal growth factor. Curr Surg. 1988 May-Jun; 45(3):204-5.
    View in: PubMed
  199. Donahoe PK. Neoseminal vesicle created from retained mullerian duct to preserve the vas in male infants. J Pediatr Surg. 1988 Mar; 23(3):272-4.
    View in: PubMed
  200. Statter MB, Foglia RP, Parks DE, Donahoe PK. Fetal and postnatal testis shows immunoprivilege as donor tissue. J Urol. 1988 Jan; 139(1):204-10.
    View in: PubMed
  201. Donahoe PK, Takahashi M, Ueno S, Manganaro TF. Mullerian inhibiting substance in the ovary. Prog Clin Biol Res. 1988; 267:153-75.
    View in: PubMed
  202. Cigarroa FG, Kim SH, Donahoe PK. Imperforate anus with long but apparent low fistula in females. J Pediatr Surg. 1988 Jan; 23(1 Pt 2):42-4.
    View in: PubMed
  203. Meyers-Wallen VN, Donahoe PK, Manganaro T, Patterson DF. Müllerian inhibiting substance in sex-reversed dogs. Biol Reprod. 1987 Nov; 37(4):1015-22.
    View in: PubMed
  204. Donahoe PK. The diagnosis and treatment of infants with intersex abnormalities. Pediatr Clin North Am. 1987 Oct; 34(5):1333-48.
    View in: PubMed
  205. Vacanti JP, Lillehei CW, Jenkins RL, Donahoe PK, Cosimi AB, Kleinman R, Grand RJ, Cho SI. Liver transplantation in children: the Boston Center experience in the first 30 months. Transplant Proc. 1987 Aug; 19(4):3261-6.
    View in: PubMed
  206. Foglia RP, Kim SH, Cleveland RH, Donahoe PK. Complications of vaginal atresia in association with a duplicated mullerian duct. J Pediatr Surg. 1987 Jul; 22(7):653-6.
    View in: PubMed
  207. Coughlin JP, Austen WG, Donahoe PK, Russell WE. Liver regeneration during immunosuppression. J Pediatr Surg. 1987 Jun; 22(6):566-70.
    View in: PubMed
  208. Donahoe PK, Cate RL, MacLaughlin DT, Epstein J, Fuller AF, Takahashi M, Coughlin JP, Ninfa EG, Taylor LA. Müllerian inhibiting substance: gene structure and mechanism of action of a fetal regressor. Recent Prog Horm Res. 1987; 43:431-67.
    View in: PubMed
  209. Coughlin JP, Donahoe PK, Budzik GP, MacLaughlin DT. Müllerian inhibiting substance blocks autophosphorylation of the EGF receptor by inhibiting tyrosine kinase. Mol Cell Endocrinol. 1987 Jan; 49(1):75-86.
    View in: PubMed
  210. Donahoe PK, Keating MA. Preputial unfurling to correct the buried penis. J Pediatr Surg. 1986 Dec; 21(12):1055-7.
    View in: PubMed
  211. Takahashi M, Koide SS, Donahoe PK. Müllerian inhibiting substance as oocyte meiosis inhibitor. Mol Cell Endocrinol. 1986 Oct; 47(3):225-34.
    View in: PubMed
  212. Foglia RP, DiPreta J, Statter MB, Donahoe PK. Fetal allograft survival in immunocompetent recipients is age dependent and organ specific. Ann Surg. 1986 Oct; 204(4):402-10.
    View in: PubMed
  213. Takahashi M, Hayashi M, Manganaro TF, Donahoe PK. The ontogeny of mullerian inhibiting substance in granulosa cells of the bovine ovarian follicle. Biol Reprod. 1986 Sep; 35(2):447-53.
    View in: PubMed
  214. Hutson JM, Donahoe PK. The hormonal control of testicular descent. Endocr Rev. 1986 Aug; 7(3):270-83.
    View in: PubMed
  215. LaQuaglia M, Shima H, Hudson P, Takahashi M, Donahoe PK. Sertoli cell production of müllerian inhibiting substance in vitro. J Urol. 1986 Jul; 136(1 Pt 2):219-24.
    View in: PubMed
  216. Foglia RP, LaQuaglia M, DiPreta J, Donahoe PK. Can fetal and newborn allografts survive in an immunocompetent host? J Pediatr Surg. 1986 Jul; 21(7):608-12.
    View in: PubMed
  217. Psihramis KE, Donahoe PK. Primary genitourinary tuberculosis: rapid progression and tissue destruction during treatment. J Urol. 1986 May; 135(5):1033-6.
    View in: PubMed
  218. Ikawa H, Kim SH, Hendren WH, Donahoe PK. Acetylcholinesterase and manometry in the diagnosis of the constipated child. Arch Surg. 1986 Apr; 121(4):435-8.
    View in: PubMed
  219. Necklaws EC, LaQuaglia MP, MacLaughlin D, Hudson P, Mudgett-Hunter M, Donahoe PK. Detection of Müllerian inhibiting substance in biological samples by a solid phase sandwich radioimmunoassay. Endocrinology. 1986 Feb; 118(2):791-6.
    View in: PubMed
  220. Cate RL, Ninfa EG, Pratt DJ, MacLaughlin DT, Donahoe PK. Development of mullerian inhibiting substance as an anti-cancer drug. Cold Spring Harb Symp Quant Biol. 1986; 51 Pt 1:641-7.
    View in: PubMed
  221. Hutson JM, Donahoe PK, Budzik GP. Mullerian inhibiting substance: a fetal hormone with surgical implications. Aust N Z J Surg. 1985 Dec; 55(6):599-605.
    View in: PubMed
  222. Fuller AF, Krane IM, Budzik GP, Donahoe PK. Mullerian inhibiting substance reduction of colony growth of human gynecologic cancers in a stem cell assay. Gynecol Oncol. 1985 Oct; 22(2):135-48.
    View in: PubMed
  223. Kamagata S, Donahoe PK. The effect of fibronectin on cholinergic differentiation of the fetal colon. J Pediatr Surg. 1985 Aug; 20(4):307-14.
    View in: PubMed
  224. Budzik GP, Donahoe PK, Hutson JM. A possible purification of mullerian inhibiting substance and a model for its mechanism of action. Prog Clin Biol Res. 1985; 171:207-23.
    View in: PubMed
  225. Hutson JM, Donahoe PK, MacLaughlin DT. Steroid modulation of Mullerian duct regression in the chick embryo. Gen Comp Endocrinol. 1985 Jan; 57(1):88-102.
    View in: PubMed
  226. Perlmutter D, Vacanti J, Donahoe P, Kleinman R. Liver transplantation in pediatric patients. Adv Pediatr. 1985; 32:177-96.
    View in: PubMed
  227. Donahoe PK, Krane I, Bogdén AE, Kamagata S, Budzik GP. Subrenal capsule assay to test the viability of parenterally delivered müllerian inhibiting substance. J Pediatr Surg. 1984 Dec; 19(6):863-9.
    View in: PubMed
  228. Donahoe PK, Hendren WH. Perineal reconstruction in ambiguous genitalia infants raised as females. Ann Surg. 1984 Sep; 200(3):363-71.
    View in: PubMed
  229. Eil C, Crawford JD, Donahoe PK, Johnsonbaugh RE, Loriaux DL. Fibroblast androgen receptors in patients with genitourinary anomalies. J Androl. 1984 Sep-Oct; 5(5):313-20.
    View in: PubMed
  230. Adzick NS, Strome M, Gang D, Donahoe PK. Cryotherapy of subglottic hemangioma. J Pediatr Surg. 1984 Aug; 19(4):353-7.
    View in: PubMed
  231. Hutson JM, Fallat ME, Donahoe PK. The fate of the grafted quail Mullerian duct in the chick embryonic coelom. J Pediatr Surg. 1984 Aug; 19(4):345-52.
    View in: PubMed
  232. Hayashi M, Shima H, Hayashi K, Trelstad RL, Donahoe PK. Immunocytochemical localization of Mullerian inhibiting substance in the rough endoplasmic reticulum and Golgi apparatus in Sertoli cells of the neonatal calf testis using a monoclonal antibody. J Histochem Cytochem. 1984 Jun; 32(6):649-54.
    View in: PubMed
  233. Ikawa H, Hutson JM, Budzik GP, Donahoe PK. Cyclic adenosine 3',5'-monophosphate modulation of mullerian duct regression. Endocrinology. 1984 May; 114(5):1686-91.
    View in: PubMed
  234. Fallat ME, Hutson JM, Budzik GP, Donahoe PK. Androgen stimulation of nucleotide pyrophosphatase during mullerian duct regression. Endocrinology. 1984 May; 114(5):1592-8.
    View in: PubMed
  235. Donahoe PK, Gee PE. Complete laryngotracheoesophageal cleft: management and repair. J Pediatr Surg. 1984 Apr; 19(2):143-8.
    View in: PubMed
  236. Ikawa H, Trelstad RL, Hutson JM, Manganaro TF, Donahoe PK. Changing patterns of fibronectin, laminin, type IV collagen, and a basement membrane proteoglycan during rat Mullerian duct regression. Dev Biol. 1984 Mar; 102(1):260-3.
    View in: PubMed
  237. Hutson JM, Donahoe PK. Improved histology for the chick-quail chimera. Stain Technol. 1984 Mar; 59(2):105-11.
    View in: PubMed
  238. Hutson JM, Fallat ME, Kamagata S, Donahoe PK, Budzik GP. Phosphorylation events during Müllerian duct regression. Science. 1984 Feb 10; 223(4636):586-9.
    View in: PubMed
  239. Fuller AF, Budzik GP, Krane IM, Donahoe PK. Müllerian inhibiting substance inhibition of a human endometrial carcinoma cell line xenografted in nude mice. Gynecol Oncol. 1984 Jan; 17(1):124-32.
    View in: PubMed
  240. Schwartz BR, Trelstad RL, Hutson JM, Ikawa H, Donahoe PK. Zinc chelation and mullerian duct regression. J Exp Pathol. 1984; 1(2):143-56.
    View in: PubMed
  241. Shima H, Donahoe PK, Budzik GP, Kamagata S, Hudson P, Mudgett-Hunter M. Production of monoclonal antibodies for affinity purification of bovine mullerian inhibiting substance activity. Hybridoma. 1984; 3(3):201-14.
    View in: PubMed
  242. Donahoe PK, Hutson JM, Fallat ME, Kamagata S, Budzik GP. Mechanism of action of Mullerian inhibiting substance. Annu Rev Physiol. 1984; 46:53-65.
    View in: PubMed
  243. Fallat ME, Hutson JM, Budzik GP, Donahoe PK. The role of nucleotide pyrophosphatase in Mullerian duct regression. Dev Biol. 1983 Dec; 100(2):358-64.
    View in: PubMed
  244. Hutson JM, Donahoe PK. Is Mullerian-inhibiting substance a circulating hormone in the chick-quail chimera? Endocrinology. 1983 Oct; 113(4):1470-5.
    View in: PubMed
  245. Donahoe PK, Hendren WH. Roux-en-Y on-line intussusception to avoid ascending cholangitis in biliary atresia. Arch Surg. 1983 Sep; 118(9):1091-4.
    View in: PubMed
  246. Pfister RC, Newhouse JH, Yoder IC, Hendren WH, Kim SH, Donahoe PK, Herrin JT. Complications of pediatric percutaneous renal procedures: incidence and observations. Urol Clin North Am. 1983 Aug; 10(3):563-71.
    View in: PubMed
  247. Budzik GP, Powell SM, Kamagata S, Donahoe PK. Mullerian inhibiting substance fractionation by dye affinity chromatography. Cell. 1983 Aug; 34(1):307-14.
    View in: PubMed
  248. MacLaughlin DT, Hutson JM, Donahoe PK. Specific estradiol binding in embryonic Mullerian ducts: a potential modulator of regression in the male and female chick. Endocrinology. 1983 Jul; 113(1):141-5.
    View in: PubMed
  249. Hutson JM, MacLaughlin DT, Ikawa H, Budzik GP, Donahoe PK. Regression of the Müllerian ducts during sexual differentiation in the chick embryo. A reappraisal. Int Rev Physiol. 1983; 27:177-224.
    View in: PubMed
  250. Mudgett-Hunter M, Budzik GP, Donahoe PK, Khaw BA, Margolies MN, Ridgeway EC, Haber E. Monoclonal antibodies as physiologic probes. Basic Life Sci. 1983; 25:101-28.
    View in: PubMed
  251. Hutson JM, Ikawa H, Donahoe PK. Estrogen inhibition of Mullerian inhibiting substance in the chick embryo. J Pediatr Surg. 1982 Dec; 17(6):953-9.
    View in: PubMed
  252. Ikawa H, Hutson JM, Budzik GP, MacLaughlin DT, Donahoe PK. Steroid enhancement of Mullerian duct regression. J Pediatr Surg. 1982 Oct; 17(5):453-8.
    View in: PubMed
  253. Strome M, Donahoe PK. Advances in management of laryngeal and subglottic stenosis. J Pediatr Surg. 1982 Oct; 17(5):591-6.
    View in: PubMed
  254. Robboy SJ, Miller T, Donahoe PK, Jahre C, Welch WR, Haseltine FP, Miller WA, Atkins L, Crawford JD. Dysgenesis of testicular and streak gonads in the syndrome of mixed gonadal dysgenesis: perspective derived from a clinicopathologic analysis of twenty-one cases. Hum Pathol. 1982 Aug; 13(8):700-16.
    View in: PubMed
  255. Hayashi A, Donahoe PK, Budzik GP, Trelstad RL. Periductal and matrix glycosaminoglycans in rat Mullerian duct development and regression. Dev Biol. 1982 Jul; 92(1):16-26.
    View in: PubMed
  256. Trelstad RL, Hayashi A, Hayashi K, Donahoe PK. The epithelial-mesenchymal interface of the male rate Mullerian duct: loss of basement membrane integrity and ductal regression. Dev Biol. 1982 Jul; 92(1):27-40.
    View in: PubMed
  257. Fuller AF, Guy S, Budzik GP, Donahoe PK. Mullerian inhibiting substance inhibits colony growth of a human ovarian carcinoma cell line. J Clin Endocrinol Metab. 1982 May; 54(5):1051-5.
    View in: PubMed
  258. Budzik GP, Hutson JM, Ikawa H, Donahoe PK. The role of zinc in Müllerian duct regression. Endocrinology. 1982 May; 110(5):1521-5.
    View in: PubMed
  259. Mudgett-Hunter M, Budzik GP, Sullivan M, Donahoe PK. Monoclonal antibody to Mullerian inhibiting substance. J Immunol. 1982 Mar; 128(3):1327-33.
    View in: PubMed
  260. Donahoe PK, Budzik GP, Trelstad R, Mudgett-Hunter M, Fuller A, Hutson JM, Ikawa H, Hayashi A, MacLaughlin D. Müllerian-inhibiting substance: an update. Recent Prog Horm Res. 1982; 38:279-330.
    View in: PubMed
  261. Hutson J, Ikawa H, Donahoe PK. The ontogeny of Mullerian inhibiting substance in the gonads of the chicken. J Pediatr Surg. 1981 Dec; 16(6):822-7.
    View in: PubMed
  262. Donahoe PK, Fuller AF, Scully RE, Guy SR, Budzik GP. Mullerian inhibiting substance inhibits growth of a human ovarian cancer in nude mice. Ann Surg. 1981 Oct; 194(4):472-80.
    View in: PubMed
  263. Donahoe PK, Kim SH. The inferior epigastric vein as an alternate site for central venous hyperalimentation. J Pediatr Surg. 1980 Dec; 15(6):737-8.
    View in: PubMed
  264. Hendren WH, Donahoe PK. Correction of congenital abnormalities of the vagina and perineum. J Pediatr Surg. 1980 Dec; 15(6):751-63.
    View in: PubMed
  265. Budzik GP, Swann DA, Hayashi A, Donahoe PK. Enhanced purification of Mullerian inhibiting substance by lectin affinity chromatography. Cell. 1980 Oct; 21(3):909-15.
    View in: PubMed
  266. Bercu BB, Hyashi A, Poth M, Alexandrova M, Soloff MS, Donahoe PK. Luteinizing hormone-releasing hormone-induced delay of parturition. Endocrinology. 1980 Aug; 107(2):504-8.
    View in: PubMed
  267. Donahoe PK, Hendren WH. Pelvic kidney in infants and children: experience with 16 cases. J Pediatr Surg. 1980 Aug; 15(4):486-95.
    View in: PubMed
  268. Kim SH, Hendren WH, Donahoe PK. Gastroesophageal reflux and hiatus hernia in children: experience with 70 cases. J Pediatr Surg. 1980 Aug; 15(4):443-51.
    View in: PubMed
  269. Price JM, Donahoe PK, Ito Y. Involution of the female Mullerian duct of the fetal rat in the organ-culture assay for the detection of Mullerian Inhibiting Substance. Am J Anat. 1979 Oct; 156(2):265-84.
    View in: PubMed
  270. Donahoe PK, Swann DA, Hayashi A, Sullivan MD. Müllerian duct regression in the embryo correlated with cytotoxic activity against human ovarian cancer. Science. 1979 Aug 31; 205(4409):913-5.
    View in: PubMed
  271. Morikawa Y, Donahoe PK, Hendren WH. Manometry and histochemistry in the diagnosis of Hirschsprung's disease. Pediatrics. 1979 Jun; 63(6):865-71.
    View in: PubMed
  272. Donahoe PK, Crawford JD, Hendren WH. Mixed gonadal dysgenesis, pathogensis, and management. J Pediatr Surg. 1979 Jun; 14(3):287-300.
    View in: PubMed
  273. Bercu BB, Morikawa Y, Jackson IM, Donahoe PK. Inhibition of Müllerian inhibiting substance secretion by FSH. Pediatr Res. 1979 Apr; 13(4 Pt 1):246-9.
    View in: PubMed
  274. Swann DA, Donahoe PK, Ito Y, Morikawa Y, Hendren WH. Extraction of Mullerian inhibiting substance from newborn calf testis. Dev Biol. 1979 Mar; 69(1):73-84.
    View in: PubMed
  275. Radhakrishnan J, Morikawa Y, Donahoe PK, Hendren WH. Observations on the gubernaculum during descent of the testis. Invest Urol. 1979 Mar; 16(5):365-8.
    View in: PubMed
  276. Bercu BB, Morikawa Y, Jackson IM, Donahoe PK. Gonadotropin control of müllerian-inhibiting substance. Pediatr Res. 1979 Feb; 13(2):142.
    View in: PubMed
  277. Adams WP, Donahoe PK. Salivary gland heterotopia in the lower part of the neck. Arch Surg. 1979 Jan; 114(1):79-81.
    View in: PubMed
  278. Morikawa Y, Donahoe PK, Hendren WH. Cholinergic nerve development of fetal lung in vitro. J Pediatr Surg. 1978 Dec; 13(6D):653-61.
    View in: PubMed
  279. Morikawa Y, Donahoe PK, Hendren WH. Cholinergic nerve development in fetal lung. Dev Biol. 1978 Aug; 65(2):541-6.
    View in: PubMed
  280. Donahoe PK, Crawford JD, Hendren WH. True hermaphroditism: a clinical description and a proposed function for the long arm of the Y chromosome. J Pediatr Surg. 1978 Jun; 13(3):293-301.
    View in: PubMed
  281. Bercu BB, Morikawa Y, Jackson IM, Donahoe PK. Increased secretion of Müllerian inhibiting substance after immunological blockade of endogenous luteinizing hormone releasing hormone in the rat. Pediatr Res. 1978 Feb; 12(2):139-42.
    View in: PubMed
  282. Ito Y, Donahoe PK, Hendren WH. Differentiation of intramural ganglia in the dissociated rectosigmoid of the rat: an organ culture study. J Pediatr Surg. 1977 Dec; 12(6):969-75.
    View in: PubMed
  283. Donahoe PK, Crawford JD, Hendren WH. Management of neonates and children with male pseudohermaphroditism. J Pediatr Surg. 1977 Dec; 12(6):1045-57.
    View in: PubMed
  284. Donahoe PK, Ito Y, Hendren WH. The preservation of Mullerian inhibiting substance during long-term freezing of testicular fragments. Cryobiology. 1977 Oct; 14(5):534-42.
    View in: PubMed
  285. Donahoe PK, Ito Y, Hendren WH. A graded organ culture assay for the detection of Mullerian inhibiting substance. J Surg Res. 1977 Aug; 23(2):141-8.
    View in: PubMed
  286. Price JM, Donahoe PK, Ito Y, Hendren WH. Programmed cell death in the Müllerian duct induced by Müllerian inhibiting substance. Am J Anat. 1977 Jul; 149(3):353-75.
    View in: PubMed
  287. Donahoe PK, Ito Y, Morikawa Y, Hendren WH. Mullerian inhibiting substance in human testes after birth. J Pediatr Surg. 1977 Jun; 12(3):323-30.
    View in: PubMed
  288. Ito Y, Donahoe PK, Hendren WH. Maturation of the rectoanal response in premature and perinatal infants. J Pediatr Surg. 1977 Jun; 12(3):477-82.
    View in: PubMed
  289. Donahoe PK, Ito Y, Price JM, Hendren WH. Müllerian inhibiting substance activity in bovine fetal, newborn and prepubertal testes. Biol Reprod. 1977 Mar; 16(2):238-43.
    View in: PubMed
  290. Raaf JH, Donahoe PK, Truman JT, Robboy SJ. Aspergillus-induced small bowel obstruction in a leukemic newborn. Surgery. 1977 Jan; 81(1):111-3.
    View in: PubMed
  291. Donahoe PK, Ito Y, Marfatia S, Hendren WH. The production of Mullerian inhibiting substance by the fetal, neonatal and adult rat. Biol Reprod. 1976 Oct; 15(3):329-34.
    View in: PubMed
  292. Donahoe PK, Hendren WH. Bile duct perforation in a newborn with stenosis of the ampulla of Vater. J Pediatr Surg. 1976 Oct; 11(5):823-5.
    View in: PubMed
  293. Donahoe PK, Hendren WH. Evaluation of the newborn with ambiguous genitalia. Pediatr Clin North Am. 1976 May; 23(2):361-70.
    View in: PubMed
  294. Hendren WH, Donahoe PK, Pfister RC. Crossed renal ectopia in children. Urology. 1976 Feb; 7(2):135-44.
    View in: PubMed
  295. Marfatia S, Donahoe PK, Hendren WH. Effect of dry and humidified gases on the respiratory epithelium in rabbits. J Pediatr Surg. 1975 Oct; 10(5):583-92.
    View in: PubMed
  296. Donahoe PK, Osmond JD, Stewart DR, Hendren WH. Renal parenchymal tolerance to artery occlusion: a time and damage study in rats developing collateral circulation. Ann Surg. 1973 Aug; 178(2):138-42.
    View in: PubMed
  297. Donahoe PK, Stewart DR, Osmond JD, Hendren WH. Pneumoperitoneum secondary to pulmonary air leak. J Pediatr. 1972 Oct; 81(4):797-800.
    View in: PubMed
  298. Donahoe PK, Hendren WH. The surgical management of laryngotracheoesophageal cleft with tracheoesophageal fistula and esophageal atresia. Surgery. 1972 Mar; 71(3):363-8.
    View in: PubMed
  299. Filler RM, Das JB, Haase GM, Donahoe PK. Muscle surface pH as a monitor of tissue perfusion and acid-base status. J Pediatr Surg. 1971 Oct; 6(5):535-42.
    View in: PubMed
  300. Donahoe PK, Froio RA, Nabseth DC. Obturator bypass graft in radical excision of inguinal neoplasm. Ann Surg. 1967 Jul; 166(1):147-9.
    View in: PubMed
  301. Rogers WM, Harrison JS, Malm JR, Thomson N, Simandl E, al-Naaman YD, Demetz A, Deterling RA, Friend W, Andrews W, Donahoe P. Phonocardiographic criteria in the diagnosis of atrial and ventricular septal defects. An experimental and clinical study. J Cardiovasc Surg (Torino). 1966 Jan-Feb; 7(1):29-33.
    View in: PubMed
  302. FRIEND WG, ANDREWS WE, DONAHOE PK, ROGERS WM. EXPERIMENTAL PRODUCTION OF ATRIAL SEPTAL DEFECTS IN DOGS; A REVIEW AND NEW TECHNIQUE. J Thorac Cardiovasc Surg. 1965 Sep; 50:444-52.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Donahoe's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Co-Authors
_
Similar People
_
Same Department
Physical Neighbors
_